Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Receivables (2016 - 2025)

Traws Pharma (TRAW) has disclosed Receivables for 12 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • For Q4 2025, Receivables rose 114.96% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, up 114.96%, while the annual FY2025 figure was $3.8 million, 114.96% up from the prior year.
  • Receivables hit $3.8 million in Q4 2025 for Traws Pharma, up from $2.0 million in the prior quarter.
  • Across five years, Receivables topped out at $3.8 million in Q4 2025 and bottomed at $17000.0 in Q1 2023.
  • Average Receivables over 5 years is $649400.0, with a median of $28000.0 recorded in 2021.
  • Year-over-year, Receivables tumbled 39.29% in 2023 and then surged 11683.33% in 2024.
  • Traws Pharma's Receivables stood at $28000.0 in 2021, then rose by 3.57% to $29000.0 in 2022, then crashed by 37.93% to $18000.0 in 2023, then surged by 9705.56% to $1.8 million in 2024, then soared by 114.96% to $3.8 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $3.8 million, $2.0 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.